{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:25:28Z","timestamp":1780082728496,"version":"3.54.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cmi.2016.12.017","type":"journal-article","created":{"date-parts":[[2016,12,26]],"date-time":"2016-12-26T05:00:33Z","timestamp":1482728433000},"page":"S125-S127","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S5","title":["Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?"],"prefix":"10.1016","volume":"22","author":[{"given":"E.A.","family":"Joura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.12.017_bib1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cmi.2015.05.001","article-title":"From the monovalent to the nine-valent HPV vaccine","volume":"21","author":"Pils","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.12.017_bib2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cmi.2016.12.017_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.cmi.2016.12.017_bib4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A\u00a0controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"9686","key":"10.1016\/j.cmi.2016.12.017_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"9574","key":"10.1016\/j.cmi.2016.12.017_bib6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.12.017_bib7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A\u00a0pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.cmi.2016.12.017_bib8","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.12.017_bib9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2013.84","article-title":"Clinical trials of human papillomavirus vaccines and beyond","volume":"10","author":"Lehtinen","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cmi.2016.12.017_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A\u00a09-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.12.017_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.017_bib12","doi-asserted-by":"crossref","first-page":"e009915","DOI":"10.1136\/bmjopen-2015-009915","article-title":"Continuing reductions in HPV 16\/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study","volume":"6","author":"Mesher","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2016.12.017_bib13","doi-asserted-by":"crossref","first-page":"djt460","DOI":"10.1093\/jnci\/djt460","article-title":"Early impact of human papillomavirus vaccination on cervical neoplasia\u2014nationwide follow-up of young Danish women","volume":"106","author":"Baldur-Felskov","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cmi.2016.12.017_bib14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cmi.2016.12.017_bib15","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cmi.2016.12.017_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"Hartwig","year":"2015","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.cmi.2016.12.017_bib17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2016.12.017_bib18","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2016.12.017_bib19","doi-asserted-by":"crossref","first-page":"e68329","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2016.12.017_bib20","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.017_bib21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.017_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/OLQ.0000000000000418","article-title":"Significant reduction in the incidence of genital warts in young men 5 years into the danish human papillomavirus vaccination program for girls and women","volume":"43","author":"Bollerup","year":"2016","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2016.12.017_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/14737167.2014.881253","article-title":"Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis","volume":"14","author":"Bresse","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.cmi.2016.12.017_bib24","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.12.017_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.12.017_bib26","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2016.12.017_bib27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.017_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cmi.2016.12.017_bib29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.017_bib30","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2016.12.017_bib31","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cmi.2016.12.017_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMe1415742","article-title":"HPV \u201ccoverage","volume":"372","author":"Schuchat","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16306346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16306346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T11:23:56Z","timestamp":1536146636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16306346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":32,"alternative-id":["S1198743X16306346"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.12.017","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}